R&D Trends

ZAI Lab, Sanofi ink agreement for chronic respiratory disease compounds

Thursday, August 14, 2014 11:43 AM

ZAI Lab, a biotech company in China, has entered into a global licensing agreement with Sanofi for two novel compounds for the potential treatment of chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF). The compounds were discovered by Sanofi and currently are in preclinical stage.

More... »

WIRB Copernicus Group

U.S. research institutions collaborate to share, standardize neuroscience databases

Wednesday, August 13, 2014 01:04 PM

The Allen Institute for Brain Science based in Seattle, Wash., the California Institute of Technology, the New York University School of Medicine, the Howard Hughes Medical Institute (HHMI) in Massachusetts and the University of California, Berkeley are collaborating on a project aimed at making databases about the brain more useable and accessible for neuroscientists—a step seen as critical to accelerating the pace of discoveries about the brain in health and disease.

More... »


Daiichi Sankyo, Charleston Laboratories collaborate on hydrocodone products for pain

Monday, August 11, 2014 01:45 PM

Daiichi Sankyo and Charleston Laboratories, through its wholly owned subsidiary LOCL Pharma, have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories’ novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of opioid-induced nausea and vomiting (OINV).

More... »

Sanofi licenses Immune Design's GLAAS platform to treat food allergies

Monday, August 11, 2014 01:38 PM

Sanofi and Immune Design, a clinical-stage immunotherapy company, have entered into a licensing agreement for use of Immune Design's GLAAS discovery platform to develop therapeutic agents to treat a selected food allergy.

More... »

Cancer Research U.K., Cancer Research Technology ink agreement with Astellas

Monday, August 11, 2014 01:35 PM

Cancer Research U.K. and its commercial arm, Cancer Research Technology (CRT), have joined with Astellas Pharma to conduct a two-year research program in the U.K. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

More... »

Igenica Biotherapeutics awarded SBIR grant for antibody drug conjugate technology

Friday, August 8, 2014 01:09 PM

Igenica Biotherapeutics, focused on the discovery and development of innovative cancer antibody-drug conjugates (ADCs), has been awarded a $215,740 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support continued development of its SNAP site-specific ADC linker technology.

More... »

MTTI, National Health Research Institutes collaborate for cancer

Thursday, August 7, 2014 12:00 PM

Molecular Targeting Technologies (MTTI), a privately held biotechnology company, and National Health Research Institutes (NHRI), Taiwan, have collaborated to develop novel cancer therapeutics using the proprietary DPA delivery technology to carry anticancer drugs that can be specifically delivered to and released at the tumor sites.

More... »

Report: Global market for DNA vaccines to reach $2.7B in 2019

Thursday, August 7, 2014 11:00 AM

According to a new BCC Research report, the global market for DNA vaccines is expected to grow to $2.7 billion by 2019, with a five-year compound annual growth rate (CAGR) of 54.8%. The clinical vaccines category, the largest and fastest-growing segment of this market, is surging at 81.2% CAGR.

More... »

Regulus Therapeutics, Biogen Idec collaborate for multiple sclerosis biomarkers

Wednesday, August 6, 2014 12:58 PM

Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, has entered into a new collaboration agreement with Biogen Idec to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. 

More... »

NIH awards $14.5M to research groups studying DNA sequencing techniques

Tuesday, August 5, 2014 09:00 AM

A number of micro-sized technologies—such as nanopores and microfluidics—are among the approaches researchers will use to develop high-quality, low-cost DNA sequencing technology through new grants from the NIH. The grants, which total approximately $14.5 million to eight research teams over two to four years as funds become available, are the last to be awarded by the Advanced DNA Sequencing Technology program of the National Human Genome Research Institute (NHGRI), a part of NIH.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs